Kynurenine: Difference between revisions
Notjusttired (talk | contribs) (potential benefits) |
Notjusttired (talk | contribs) m (→References: cat) |
||
| Line 43: | Line 43: | ||
==References== | ==References== | ||
{{Reflist}} | |||
[[Category:Amino acids]] | [[Category:Amino acids]] | ||
| Line 48: | Line 49: | ||
[[Category:Energy system]] | [[Category:Energy system]] | ||
[[Category:Metabolism]] | [[Category:Metabolism]] | ||
[[Category:Potential treatments]] | |||
Revision as of 12:40, July 3, 2020
Kynurenine is an amino acid that is produced in the body by the metabolism of the essential amino acid tryptophan.[1][2]
ME/CFS[edit | edit source]
The Open Medicine Foundation's ME/CFS Severely Ill, Big Data Study found that patients in the study group with severe ME had one of several defects involving the IDO2 gene, which affected tryptophan - kynurenine metabolism.[3] This lead to the Metabolic Trap theory.[3]
Uppsala trial, Sweden[edit | edit source]
In May 2020, the Open Medicine Foundation announced a pilot treatment trial of kynurenine for ME/CFS.[4] Dr Jonas Bergquist will be running the trial.[5]
Trial type[edit | edit source]
Pilot trial, with cross-over at 3 months. Patients receiving the kynurenine will change to the placebo after 3 months, and patients receiving the placebo will switch to the kynurenine. No control group.[4][5]
Aims[edit | edit source]
To see whether kynurenine improves cognitive impairment (brain fog), headaches and memory in ME/CFS patients.[5]
Patients[edit | edit source]
Only 20 out of a group of 100 ME/CFS patients. Patients will be those identified as having a low level of kynurenine in blood serum and ME/CFS.[5]
Outcomes[edit | edit source]
Measurements will be taken from wearable sensors.[5]
Potential benefits[edit | edit source]
Kynurenine might be beneficial to ME/CFS patients; the Open Medicine Foundation's kynurenine trial aims to investigate this.
Suppose that some brain cells in a particular brain nucleus are in the IDO metabolic trap. This means that in those cells the concentration of tryptophan is too high, and the concentration of kynurenine is too low.Supplying an outside source of kynurenine, as Dr. Bergquist proposes, could conceivably solve part of the problem by allowing those brain cells to make the neuroactive metabolites of kynurenine that they cannot make if the metabolic trap has been sprung. So, the clinical trial might improve symptoms caused by too little kynurenine or too little kynurenic acid, a known neuroprotectant.
Dr. Bergquist's expertly designed clinical trial of kynurenine in ME/CFS to improve brain fog, memory, and headache is both important and timely.[6]
— Robert Phair, Kynurenine and the Metabolic Trap Hypothesis
Learn more[edit | edit source]
- Kynurenine - PubChem
- L-Kynurenine - PubChem
- Kynurenine clinical trial - Open Medicine Foundation
See also[edit | edit source]
References[edit | edit source]
- ↑ "Medical Definition of KYNURENINE". www.merriam-webster.com. Retrieved November 30, 2019.
- ↑ National Center for Biotechnology Information. "Kynurenine". PubChem Database. Retrieved January 19, 2020. Cite has empty unknown parameter:
|dead-url=(help) - ↑ 3.0 3.1 Phair, Robert D.; Davis, Ronald W.; Kashi, Alex A. (2019). "The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS". Diagnostics. 9 (3): 82. doi:10.3390/diagnostics9030082.
- ↑ 4.0 4.1 Open Medicine Foundation. "#May Momentum 2020". Open Medicine Foundation. Retrieved May 1, 2020. Cite has empty unknown parameter:
|dead-url=(help) - ↑ 5.0 5.1 5.2 5.3 5.4 Open Medicine Foundation (April 26, 2020). "Kynurenine Clinical Trial for ME / CFS". Open Medicine Foundation. Retrieved May 5, 2020. Cite has empty unknown parameter:
|dead-url=(help) - ↑ https://www.omf.ngo/2020/05/26/omf-announces-new-treatment-trial/?utm_source=facebook
